Psoriatic arthritis management update - biotherapeutic options.

Hdl Handle:
http://hdl.handle.net/10147/207521
Title:
Psoriatic arthritis management update - biotherapeutic options.
Authors:
Saber, Tajvur P; Veale, Douglas J
Affiliation:
Centre for Arthritis Research and Education, Dublin Academic Health Care, St., Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
Citation:
J Rheumatol Suppl. 2009 Aug;83:65-8.
Journal:
The Journal of rheumatology. Supplement
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207521
DOI:
10.3899/jrheum.090229
PubMed ID:
19661546
Abstract:
Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy (SpA) occurring in up to 30% of patients with psoriasis. It has a wide variation of annual incidence (median 6.4, range 0.1-3.1 per 10(5) people), based on analysis of 13 incidence and prevalence reviews published between 1987 and December 2006. Conventional treatments with antiinflammatory and disease modifying or antirheumatic drugs are not efficacious in all patients, in particular those with axial disease. This review examines new pharmacological developments in the treatment of PsA with a focus on biologic therapies.
Language:
eng
MeSH:
Arthritis, Psoriatic/*drug therapy; Biological Factors/*therapeutic use; Clinical Trials as Topic; Humans; Tumor Necrosis Factor-alpha/*antagonists & inhibitors
ISSN:
0380-0903 (Print); 0380-0903 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorSaber, Tajvur Pen_GB
dc.contributor.authorVeale, Douglas Jen_GB
dc.date.accessioned2012-02-01T10:30:11Z-
dc.date.available2012-02-01T10:30:11Z-
dc.date.issued2012-02-01T10:30:11Z-
dc.identifier.citationJ Rheumatol Suppl. 2009 Aug;83:65-8.en_GB
dc.identifier.issn0380-0903 (Print)en_GB
dc.identifier.issn0380-0903 (Linking)en_GB
dc.identifier.pmid19661546en_GB
dc.identifier.doi10.3899/jrheum.090229en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207521-
dc.description.abstractPsoriatic arthritis (PsA) is a seronegative spondyloarthropathy (SpA) occurring in up to 30% of patients with psoriasis. It has a wide variation of annual incidence (median 6.4, range 0.1-3.1 per 10(5) people), based on analysis of 13 incidence and prevalence reviews published between 1987 and December 2006. Conventional treatments with antiinflammatory and disease modifying or antirheumatic drugs are not efficacious in all patients, in particular those with axial disease. This review examines new pharmacological developments in the treatment of PsA with a focus on biologic therapies.en_GB
dc.language.isoengen_GB
dc.subject.meshArthritis, Psoriatic/*drug therapyen_GB
dc.subject.meshBiological Factors/*therapeutic useen_GB
dc.subject.meshClinical Trials as Topicen_GB
dc.subject.meshHumansen_GB
dc.subject.meshTumor Necrosis Factor-alpha/*antagonists & inhibitorsen_GB
dc.titlePsoriatic arthritis management update - biotherapeutic options.en_GB
dc.contributor.departmentCentre for Arthritis Research and Education, Dublin Academic Health Care, St., Vincent's University Hospital, Elm Park, Dublin 4, Ireland.en_GB
dc.identifier.journalThe Journal of rheumatology. Supplementen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.